Skip to Main Content
TABLE 3

Recognition of viral peptides by PBMCs of patients and of control individuals

V*EpitopeSequenceHLAFrequencies of recognition
Responses§
PatientsControl subjectsPatientsControl subjectsComparison (P)
IV M0. 58–66 GILGFVFTL A2 18/20 8/11 89 (0–676) 49 (0–246) 0.36 
IV NP 44–52 CTELKLSDY A1 3/6 3/3 39 (7–40) 14 (10–20) 0.43 
IV NP 380–388 ELRSRYWAI B8 7/13 2/7 8 (0–119) 5 (2–131) 0.30 
HIV Nef 83–91 AAVDLSHFL A2 0/12 0/4 3 (0–20) 0 (0–5) 0.06 
HIV Nef 182–189 EWRFDSRLA B8 0/8 0/3 1 (0–35) 0 (0–0) 0.07 
V*EpitopeSequenceHLAFrequencies of recognition
Responses§
PatientsControl subjectsPatientsControl subjectsComparison (P)
IV M0. 58–66 GILGFVFTL A2 18/20 8/11 89 (0–676) 49 (0–246) 0.36 
IV NP 44–52 CTELKLSDY A1 3/6 3/3 39 (7–40) 14 (10–20) 0.43 
IV NP 380–388 ELRSRYWAI B8 7/13 2/7 8 (0–119) 5 (2–131) 0.30 
HIV Nef 83–91 AAVDLSHFL A2 0/12 0/4 3 (0–20) 0 (0–5) 0.06 
HIV Nef 182–189 EWRFDSRLA B8 0/8 0/3 1 (0–35) 0 (0–0) 0.07 

Data are n or median (mean).

*

V, virus; IV, influenza virus.

HLA, presenting HLA molecule.

ELISpot responses, number of responders/number of individuals tested.

§

Median (range) of stimulation score; stimulation score = mean number of spots in response to peptide − mean number of spots in absence of peptide; P, P values comparing the median responses in patients versus control subjects; nonparametric Mann-Whitney test.

Close Modal

or Create an Account

Close Modal
Close Modal